Hematologic Malignancy
Lymphoid Neoplasm
CI-CAN-00009335Explore in graph →
Hematologic2,419 active trials60 approved drugs271 evidence items
- OncoTree
- LNM
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00009335Explore in graph →
Clinical trials
8,885 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,373)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07297160 | CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors(CALySSEY) | withdrawn | Phase 1 | 0 | Baylor College of MedicineOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04579523 | ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma | withdrawn | Phase 1 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 |
| Sep 11, 2026 |
| clinicaltrials |
| NCT06703216 | Pre-emptive Anakinra for Cytokine Event Reduction(PACER) | withdrawn | Phase 1 / Phase 2 | 0 | Kevin McNerneyOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07082270 | Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma | withdrawn | Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07585734 | Clinical Trial of CD38 Monoclonal Antibody Combined With Chemotherapy for T-Cell Acute Lymphoblastic Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | May 14, 2026 | clinicaltrials |
| NCT06698744 | UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma | withdrawn | Phase 1 | 0 | David WaldOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06767956 | Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy | withdrawn | Phase 1 / Phase 2 | 0 | University of PittsburghOTHER | 0 | Apr 13, 2026 | clinicaltrials |
| NCT07049432 | N-803 Maintenance Therapy Post CAR T-cell Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas(CARMEN-803) | withdrawn | Phase 1 | 0 | University of UtahOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT05909527 | A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | Guangzhou Bio-gene Technology Co., LtdINDUSTRY | 1 | Mar 17, 2026 | clinicaltrials |
| NCT05170828 | Cryopreserved MMUD BM With PTCy for Hematologic Malignancies | withdrawn | Phase 1 | 0 | Ossium Health, Inc.INDUSTRY | 0 | Feb 24, 2026 | clinicaltrials |
| NCT07071909 | Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells | withdrawn | Phase 1 / Phase 2 | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT04398680 | A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function(DREAMM 13) | withdrawn | Phase 1 | 0 | GlaxoSmithKlineINDUSTRY | 3 | Dec 4, 2025 | clinicaltrials |
| NCT02315157 | Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma | withdrawn | Phase 1 | 0 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Oct 15, 2025 | clinicaltrials |
| NCT04372641 | Testing the Safety of CB-5339 in Patients With Cancer | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Sep 17, 2025 | clinicaltrials |
| NCT06005649 | Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | Juventas Cell Therapy Ltd.INDUSTRY | 0 | Aug 8, 2025 | clinicaltrials |
| NCT06009107 | A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL)(B-ALL) | withdrawn | Phase 1 / Phase 2 | 0 | Juventas Cell Therapy Ltd.INDUSTRY | 0 | Aug 8, 2025 | clinicaltrials |
| NCT05538988 | BIOmarker-guided Study to Evaluate the Efficacy and Safety of cemipLimab for advancEd Cutaneous T-cell Lymphoma(BIOSELECT) | withdrawn | Phase 1 / Phase 2 | 0 | AHS Cancer Control AlbertaOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT06290622 | PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL | withdrawn | Phase 1 | 0 | University of Alabama at BirminghamOTHER | 0 | May 6, 2025 | clinicaltrials |
| NCT02548468 | Reduced Intensity Conditioning Before Partially Matched Donor Stem Cell Transplant in Treating Patients With Advanced Cutaneous T Cell Lymphoma | withdrawn | Phase 1 | 0 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 0 | May 2, 2025 | clinicaltrials |
| NCT05486481 | Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE) | withdrawn | Phase 1 / Phase 2 | 0 | Alfred Chung, MDOTHER | 0 | Mar 6, 2025 | clinicaltrials |
| NCT04781855 | Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Feb 28, 2025 | clinicaltrials |
| NCT04148742 | Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3) | withdrawn | Phase 1 / Phase 2 | 0 | Dizal PharmaceuticalsINDUSTRY | 1 | Feb 25, 2025 | clinicaltrials |
| NCT03169790 | QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL | withdrawn | Phase 1 / Phase 2 | 0 | ImmunityBio, Inc.INDUSTRY | 0 | Feb 24, 2025 | clinicaltrials |
| NCT04052061 | QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma | withdrawn | Phase 1 | 0 | ImmunityBio, Inc.INDUSTRY | 1 | Feb 21, 2025 | clinicaltrials |
| NCT02743546 | Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma | withdrawn | Phase 1 | 0 | Janssen Research & Development, LLCINDUSTRY | 0 | Feb 3, 2025 | clinicaltrials |
| NCT06411301 | A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors(AcTRESS) | withdrawn | Phase 1 | 0 | Jules Bordet InstituteOTHER | 1 | Jan 31, 2025 | clinicaltrials |
| NCT06050512 | Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma | withdrawn | Phase 1 / Phase 2 | 0 | Kathleen DorritieOTHER | 0 | Nov 19, 2024 | clinicaltrials |
| NCT03417765 | Safety, Tolerability, PK/PD of FE 203799 in Adults With Lymphomas | withdrawn | Phase 1 / Phase 2 | 0 | GlyPharma TherapeuticsINDUSTRY | 0 | Oct 24, 2024 | clinicaltrials |
| NCT05134740 | (TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL).(pediTACTAL) | withdrawn | Phase 1 | 0 | Baylor College of MedicineOTHER | 1 | Oct 22, 2024 | clinicaltrials |
| NCT05936229 | Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy | withdrawn | Phase 1 / Phase 2 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 12, 2024 | clinicaltrials |
| NCT05950113 | CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma | withdrawn | Phase 1 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 1, 2024 | clinicaltrials |
| NCT04995536 | CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 0 | Apr 25, 2024 | clinicaltrials |
| NCT05613348 | CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma(CAR19T2) | withdrawn | Phase 1 / Phase 2 | 0 | Zhujiang HospitalOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT04466475 | Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma | withdrawn | Phase 1 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT05980507 | An Open Label, Single-arm Clinical Study Evaluating the Safety and Efficacy of ICI201 Infusion in Relapsed/Refractory Multiple Myeloma | withdrawn | Phase 1 | 0 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Dec 22, 2023 | clinicaltrials |
| NCT05321940 | Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias | withdrawn | Phase 1 | 0 | Juan C. Ramos, MDOTHER | 0 | Dec 4, 2023 | clinicaltrials |
| NCT04864522 | Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple Myeloma(MM FPBMC) | withdrawn | Phase 1 / Phase 2 | 0 | University of VirginiaOTHER | 1 | Nov 21, 2023 | clinicaltrials |
| NCT05647512 | Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases | withdrawn | Phase 1 / Phase 2 | 0 | LaNova Medicines LimitedINDUSTRY | 0 | Nov 18, 2023 | clinicaltrials |
| NCT05867030 | Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma | withdrawn | Phase 1 | 0 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 0 | Oct 17, 2023 | clinicaltrials |
| NCT05961696 | A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT03701321 | Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Sep 26, 2023 | clinicaltrials |
| NCT03884972 | Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2023 | clinicaltrials |
| NCT04952584 | Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas | withdrawn | Phase 1 | 0 | Baylor College of MedicineOTHER | 1 | Sep 7, 2023 | clinicaltrials |
| NCT05320380 | A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat | withdrawn | Phase 1 / Phase 2 | 0 | Children's Oncology GroupNETWORK | 0 | Sep 1, 2023 | clinicaltrials |
| NCT05519527 | STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL Amyloidosis | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Aug 31, 2023 | clinicaltrials |
| NCT04029038 | Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 21, 2023 | clinicaltrials |
| NCT05918250 | mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | withdrawn | Phase 1 | 0 | ModernaTX, Inc.INDUSTRY | 2 | Aug 18, 2023 | clinicaltrials |
| NCT05604417 | Zandelisib + Tazemetostat in R/R Follicular Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | Jacob Soumerai, MDOTHER | 0 | Jul 7, 2023 | clinicaltrials |
| NCT05934097 | FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma | withdrawn | Phase 1 | 0 | Fate TherapeuticsINDUSTRY | 0 | Jul 6, 2023 | clinicaltrials |
| NCT05037669 | Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma | withdrawn | Phase 1 | 0 | University of PennsylvaniaOTHER | 0 | Jun 22, 2023 | clinicaltrials |
Data updated 13 days agoSource updated Sep 16, 2026source: clinicaltrials